Amgen reports positive Phase III GLAGOV trial of Repatha to treat coronary heart disease
Amgen has reported positive results from its Phase III GLAGOV trial of Repatha (evolocumab) added to optimised statin therapy in treating statistically significant regression of atherosclerosis in patients with coronary artery disease (CAD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cholesterol | Coronary Heart Disease | Heart | Heart Disease | Pharmaceuticals | Statin Therapy | Statistics